Management Strategies for Nocturia – Beyond the Abstract
management strategies for nocturia, nocturnal polyuria, diminished bladder capacity, global polyuria, association between hypertension and nocturia, severe symptomatic nocturia,
Related Articles
Avelumab’s Survival Impact in Diabetic vs Non-Diabetic Bladder Cancer Patients – Shilpa Gupta
Ashish Kamat speaks with Shilpa Gupta about the JAVELIN trial and its impact on bladder cancer treatment. Dr. Gupta discusses how this study established avelumab…
How are we Getting Paid for Theranostics and Dosimetry? “Presentation” – Denise Merlino
At the 2025 UCSF-UCLA PSMA Conference, Denise Merlino addresses theranostics and dosimetry reimbursement for US clinicians. She emphasizes successful payment requires educating payers, using appropriate…
PSMA-Targeted Antibodies for Prostate Cancer Radioligand Therapy “Presentation” – Scott Tagawa
At the 2025 UCSF-UCLA PSMA Conference, Dr. Tagawa discusses PSMA-targeting antibodies versus small molecule approaches for prostate cancer therapy. He highlights antibodies’ distinct pharmacokinetics, circulating…
Combining Alpha and Beta Emitters in PSMA-Targeted Prostate Cancer Therapy – Scott Tagawa
Pedro Barata interviews Scott Tagawa about radioligand therapy research, focusing on actinium-225 PSMA antibody constructs. Dr. Tagawa explains that antibodies like rosopatamab offer advantages over…
Comparing Traditional Risk Groups vs AI Analysis in Prostate Cancer Management, Journal Club – Jonathan Tward & Ashley Ross
Matthew Cooperberg moderates a patient-oriented discussion with Jonathan Tward and Ashley Ross about a prostate cancer test that uses artificial intelligence to analyze digital pathology…
SNMMI 2025: STARLiT: Stereotactic Body Radiotherapy and 177Lu PSMA-617 in Locally Advanced Prostate Cancer
SNMMI 2025 STARLiT trial, stereotactic body radiotherapy (SBRT) plus 177Lu PSMA-617 in patients with locally advanced prostate cancer, ADT +/- abiraterone/prednisone.
The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country
International guidelines recommend salvage radiotherapy (sRT) as a curative treatment for men with biochemically recurrent prostate cancer after radical prostatectomy. Prostate-specific membrane antigen (PSMA) PET/CT…
PRECISION Data Platform Reveals mCRPC Treatment Outcomes in Urology Practices – Neal Shore
Zachary Klaassen interviews Neal Shore about real-world treatment patterns for mCRPC patients in community urology centers using the PRECISION database. Dr. Shore analyzes data from…
SNMMI 2025: A Combination of a CD46-Targeted Antibody-Drug Conjugate and a Radioimmunotherapy Agent for the Treatment of Prostate Cancer
SNMMI 2025, Prostate Cancer, Radioimmunotherapy Agent, CD46-Targeted Antibody-Drug Conjugate, CD46-Targeted Antibody-Drug Conjugate and a Radioimmunotherapy Agent for the Treatment of Prostate Cancer, anti-CD46 targeted antibody,…
Interdisciplinary GU Cancer Forum 2025: Novel Agents in Metastatic Urothelial Carcinoma
Interdisciplinary GU Cancer Forum 2025, Metastatic Urothelial Carcinoma, enfortumab vedotin, Nectin-4 antibody drug conjugate, CRB-701, BT8009-100, DURAVELO-1 trial, DURAVELO-2 trial, zelenectide pevedotin, pembrolizumab, zelenectide pevedotin…